Physician profile
Bassel Kisso
NPI 1093918302
$10,653.24
in general payments reported to CMS, 2019-2025
43 companies · $2,433 in 2025
The $2,433 reported for 2025 was more than what 83% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $762 · 2020: $463 · 2021: $1,015 · 2022: $1,666 · 2023: $2,041 · 2024: $2,273 · 2025: $2,433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,635 · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,634.54 |
| Education | $112.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,739.84 | 2019-2025 | |
| Janssen Biotech, INC. | $1,588.51 | 2019-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $851.07 | 2019-2025 | Entyvio, Eohilia |
| Celgene Corporation | $724.74 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $567.51 | 2019-2025 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $460.64 | 2019-2025 | |
| Pfizer INC. | $385.27 | 2019-2025 | |
| Genzyme Corporation | $349.12 | 2022-2025 | |
| Ardelyx, INC. | $228.13 | 2023-2025 | Ibsrela |
| Lilly USA, LLC | $218.09 | 2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $215.51 | 2022-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $194.11 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $186.60 | 2022-2023 | Zeposia |
| Nestle Healthcare Nutrition INC. | $177.46 | 2020-2023 | |
| Ferring Pharmaceuticals INC. | $174.63 | 2019-2025 | Rebyota |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $174.40 | 2023 | Signia |
| Aimmune Therapeutics, INC. | $171.66 | 2024-2025 | Zenpep, Vowst |
| Qol Medical, LLC | $158.56 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $146.05 | 2025 | Terlivaz |
| Ironwood Pharmaceuticals, INC | $137.30 | 2019-2025 | |
| Braintree Laboratories, INC. | $81.76 | 2021-2024 | Sutab, Suflave |
| Phathom Pharmaceuticals, INC. | $80.10 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $63.15 | 2019-2023 | Dificid |
| Madrigal Pharmaceuticals | $62.77 | 2024-2025 | Rezdiffra, Resmetirom |
| Evoke Pharma, INC. | $57.56 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $56.70 | 2024-2025 | Iqirvo |
| Alnylam Pharmaceuticals INC. | $54.79 | 2023 | Givlaari |
| Celltrion USA INC. | $51.65 | 2024-2025 | Vegzelma |
| Shionogi INC | $51.24 | 2019 | |
| Ambu INC. | $49.95 | 2020 | |
| Abbott Laboratories | $48.12 | 2023 | Mitraclip |
| Boston Scientific Corporation | $34.34 | 2022 | |
| Biogen, INC. | $33.38 | 2022 | |
| Ethicon US, LLC | $29.72 | 2020-2021 | |
| Novo Nordisk INC | $21.36 | 2025 | Wegovy |
| Redhill Biopharma INC. | $15.05 | 2024 | Talicia |
| Alfasigma USA, INC. | $12.40 | 2020 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bassel Kisso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.